OncoMed Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
July 17 2013 - 8:00PM
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), today announced the
pricing of its initial public offering of 4,800,000 shares of its
common stock at a price to the public of $17.00 per share. The
shares are expected to begin trading on The NASDAQ Global Select
Market on Thursday, July 18, 2013 under the ticker symbol "OMED."
All of the shares of common stock are being offered by OncoMed. In
addition, OncoMed has granted the underwriters a 30-day option to
purchase up to an additional 720,000 shares of common stock.
Jefferies LLC and Leerink Swann are acting as joint book-running
managers for the offering. Piper Jaffray and BMO Capital Markets
are acting as co-managers.
This offering is being made solely by means of a prospectus,
copies of which may be obtained from Jefferies LLC, Equity
Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor,
New York, NY 10022, or by calling 877-547-6340, or by e-mailing
Prospectus_Department@Jefferies.com; or Leerink Swann LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at 1-800-808-7525 or by email at
Syndicate@Leerink.com.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission on
July 17, 2013. This press release shall not constitute an offer to
sell or the solicitation of an offer to buy, nor shall there be any
sale of these securities in any state or jurisdiction in which such
an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About OncoMed Pharmaceuticals, Inc.
OncoMed Pharmaceuticals is a clinical-stage company focused on
discovering and developing novel therapeutics targeting cancer stem
cells, or CSCs, which are the subpopulation of cells in a tumor
responsible for driving growth and metastasis of the tumor. OncoMed
has five anti-CSC product candidates in clinical development,
including demcizumab (OMP-21M18, anti-DLL4), OMP-59R5
(anti-Notch2/3), OMP-52M51 (anti-Notch1), vantictumab (OMP-18R5,
anti-Fzd7), and OMP-54F28 (Fzd8-Fc), which target key cancer stem
cell signaling pathways including Notch and Wnt. OncoMed has two
other antibodies in preclinical development with Investigational
New Drug filings planned for as early as 2014. OncoMed is also
pursuing discovery of additional novel anti-CSC product candidates.
OncoMed has formed strategic alliances with Bayer Pharma AG and
GlaxoSmithKline.
CONTACT: Investor Contacts:
OncoMed Pharmaceuticals
Shari Annes
Investor Relations
(650) 888-0902
shari.annes@oncomed.com
Media Inquiries:
BCC Partners
Karen L. Bergman or
Michelle Corral
(650) 575-1509 or (415) 794-8662
kbergman@bccpartners.com or
mcorral@bccpartners.com
ONCOMED PHARMACEUTICALS INC (NASDAQ:OMED)
Historical Stock Chart
From Apr 2024 to May 2024
ONCOMED PHARMACEUTICALS INC (NASDAQ:OMED)
Historical Stock Chart
From May 2023 to May 2024